Clinical trials: Oxaliplatin
Mesothelioma; Peritoneum, Pseudomyxoma Peritonei
Thrombin Generation and Platelet Activation in CRS/HIPEC
Cytoreductive surgery (CRS) with hyperthermic intraperitoneal peroperative chemotherapy (HIPEC), indicated for patients with peritoneal metastases from digestive or gynecological malignancies alike, demonstrates a considerable…
- Conditions
- Mesothelioma; Peritoneum, Pseudomyxoma Peritonei, Peritoneal Carcinomatosis
- Trial name
- NCT03034850
- Testing
- CRS/HIPEC
- Volunteers
- 27 people
- Sponsor
- Ziekenhuis Oost-Limburg
Colorectal Cancer
Feasibility Study of mFOLFOX6 in Patients With Advanced Colorectal Cancer
We performed a feasibility study of mFOLFOX6 in advanced colorectal cancer in Japan and to estimate the safety and efficacy of this regimen.
- Trial name
- NCT00209703
- Testing
- Oxaliplatin, l-Leucovorin, 5-Fluorouracil
- Where
- Japan
- Volunteers
- 30 people
- Sponsor
- Hokkaido Gastrointestinal Cancer Study Group
Metastatic Colorectal Cancer
Metformin and 5-fluorouracil for Refractory Colorectal Cancer.
This is a phase II trial to evaluate efficacy and safety of Metformin and Fluorouracil in patients with metastatic colorectal cancer (CRC) who have progressed after Oxaliplatin and Irinotecan based chemotherapy.
- Trial name
- NCT01941953
- Testing
- Metformin and Fluorouracil
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Germ Cell Tumour
A Novel Single Arm Phase II Study for Relapsed Germ Cell Tumours With Poor Prognosis
The treatment of germ cell tumours is considered to be one of the major successes in the area of cytotoxic chemotherapy. Even in patients who relapse after first line therapy, a durable remission rate of between 25% and 60% has…
- Trial name
- GAMMA (NCT01782339)
- Testing
- Combination Chemotherapy
- Where
- United Kingdom
- Volunteers
- 45 people
- Sponsor
- Barts & The London NHS Trust
Locally Advanced Rectal Cancer (LARC)
XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients
This is a phase II, multicenter, randomized (2:1) controlled, clinical trial to evaluate the preliminary efficacy and safety of consolidation chemotherapy (XELOX) plus dostarlimab after standard long-course CRT (ARM A) compared…
- Trial name
- IMMUNOSTAR (NCT07381777)
- Testing
- XELOX (Capecitabine and Oxaliplatin), Dostarlimab
- Where
- 30 sites in Italy
- Volunteers
- 270 people
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
Locally Advanced Pancreatic Cancer, Irreversible Electroporation
Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer
Background Pancreatic cancer is one the leading causes of cancer-related death in Canada. Approximately 40 percent of patients with pancreatic cancer present with locally advanced pancreatic cancer and are not candidate for…
- Trial name
- SMART (NCT04276857)
- Testing
- Irreversible electroporation (NanoKnife® )
- Where
- 2 sites in Canada
- Volunteers
- 27 people
- Sponsor
- University of Saskatchewan
Colorectal Cancer
Prospective Study on the Efficacy and Safety of 2 Week or 3 Week Xelox Regimen for Adjuvant Chemotherapy in CRC
This study select the diagnosis of postoperative colorectal cancer patients with stage II/III to adjuvant chemotherapy, and received 2 weeks and 3 weeks xelox adjuvant treatment process until disease progression or patients died…
- Trial name
- NCT03564912
- Testing
- Capecitabine Oral Tablet [Xeloda]
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Zhejiang University
Advanced Cancers
Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab
The goal of this clinical research study is to find the best combination of oxaliplatin, bevacizumab, 5-fluorouracil, leucovorin, and cetuximab that can be given to patients with advanced cancer that has spread to the liver.
- Trial name
- NCT00941499
- Testing
- HAI Oxaliplatin, 5-FU, Bevacizumab
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- M.D. Anderson Cancer Center
Non-Hodgkin's Lymphoma
Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin as 2nd Line Therapy for Non-Hodgkin's Lymphoma (NHL)
Oxaliplatin will be used instead of cisplatin in well-known salvage regimen of etoposide, methylprednisolone, cytarabine and cisplatin (ESHAP).
- Trial name
- NCT00336583
- Testing
- Oxaliplatin
- Where
- South Korea
- Volunteers
- 27 people
- Sponsor
- Asan Medical Center
Metastatic Colorectal Cancer, Stage II/III Colon Cancer
A Screening Study Targeting Tumor-specific Antigens
The purpose of this study is to identify patients who may be eligible to participate in a separate Phase 2/3 treatment study evaluating an individualized neoantigen vaccine GRANITE for first line (1L) maintenance treatment of…
- Trial name
- NCT05158621
- Testing
- blood collection for research (next generation sequencing [NGS]), blood collection for research (HLA typing), blood collection for research (circulating tumor DNA [ctDNA])
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Gritstone bio, Inc.
Liver Disease
Oxaliplatin to Treat Advanced Cancers With Liver Dysfunction
This is a phase I study of the experimental anticancer drug oxaliplatin. It is designed to establish the maximum dose of the drug that can be given safely to patients with cancer who have impaired liver function and to determine…
- Trial name
- NCT00006062
- Testing
- oxaliplatin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
Construction of a Recurrence Risk Prediction Model for Liver Resection Based on Drug Sensitivity of Patient-derived Hepatocellular Carcinoma Organoid
Liver cancer is the sixth most common malignant tumor worldwide and the third leading cause of cancer-related deaths. China is a high-risk area for liver cancer, accounting for approximately 55% of primary liver cancer worldwide.
- Trial name
- NCT06699524
- Testing
- in vitro （chemotherapy）, Adjuvant TACE（Adjuvant Transarterial Chemoembolization）
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Shen Feng
Stage II Colon Cancer, Stage III Colon Cancer
Fluorouracil Plus Leucovorin With or Without Oxaliplatin in Treating Patients With Stage II or Stage III Colon Cancer
Randomized phase III trial to compare the effectiveness of fluorouracil plus leucovorin with or without oxaliplatin in treating patients who have stage II or stage III colon cancer.
- Trial name
- NCT00004931
- Testing
- leucovorin calcium, fluorouracil, oxaliplatin
- Where
- United States
- Volunteers
- 2,472 people
- Sponsor
- National Cancer Institute (NCI)
Peritoneal Carcinomatosis, Gastric Cancer
Neo-adjuvant Chemo + Peritonectomy + Hyperthermic Intraperitoneal Chemo in Peritoneal Carcinomatosis From Gastric Cancer
The aims of this study are to investigate whether multimodal treatment of peritoneal carcinomatosis from gastric cancer is feasible and to evaluate the clinical outcomes and clinical effectiveness of neoadjuvant systemic…
- Trial name
- NCT01379482
- Testing
- Multimodal treatment
- Where
- Sweden
- Volunteers
- 18 people
- Sponsor
- Uppsala University
Hepatocellular Carcinoma (HCC), Second Line Treatment
A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular Carcinoma
The goal of this prospective Phase II clinical trial is to evaluate the efficacy and safety of QL1706-based combination therapy in patients with hepatocellular carcinoma (HCC) who have failed prior targeted-immunotherapy (e.g.…
- Trial name
- DRIVE-II (NCT07138885)
- Testing
- HAI-FOLFOX + bevacizumab + QL1706, TACE + bevacizumab + TAS-102 + QL1706
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Sun Yat-sen University
Colorectal Neoplasm
Recombinant Human Endostatin in Combination With mFOLFOX6 in Patients With Metastatic Colorectal Cancer
To investigate safety and tolerance of dose-escalation of infusional recombinant human endostatin in combination with mFOLFOX6 as initial therapy for patients with metastatic colorectal cancer.
- Trial name
- NCT01310478
- Testing
- recombinant human endostatin (Endostat)
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Fudan University
Colon Cancer
Adjuvant Colon Cancer w/ ELOXatin®/5 FU Based Regimen: ACCELOX
Adjuvant Colon Cancer With ELOXatin®/5 FU Based Regimen: ACCELOX
- Trial name
- NCT01310972
- Testing
- Registry
- Where
- Saudi Arabia
- Volunteers
- 6 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Hepatoblastoma, Carcinoma, Hepatocellular
Paediatric Hepatic International Tumour Trial
The PHITT trial is an over-arching study for patients with Hepatoblastoma (HB) and Hepatocellular Carcinoma (HCC). This trial will use a risk-adapted approach to the treatment of children diagnosed with HB.
- Trial name
- PHITT (NCT03017326)
- Testing
- Cisplatin, Doxorubicin, Carboplatin
- Where
- 32 sites in Austria, Belgium and 12 more
- Volunteers
- 450 people
- Sponsor
- University of Birmingham
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver
Phase II trial to study the effectiveness of hepatic arterial infusion plus chemotherapy in treating patients who have colorectal cancer metastatic to the liver.
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Liver Metastases, Recurrent Colon Cancer
- Trial name
- NCT00026234
- Testing
- floxuridine, dexamethasone, oxaliplatin
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
Neuropathy, Cancer
Glutamine for the Prophylaxis of Vincristine-induced Neuropathy in Children and Adolescents With Cancer.
The goal of this clinical trial is to assess the efficacy of glutamine in preventing the occurrence of vincristine induced neuropathy and to compare the reduction in rate of any dose reductions and premature chemotherapy…
- Trial name
- NCT07287592
- Testing
- Glutamine (Pharmacological doses)
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Ain Shams University